Mycophenolate Mofetil Injection Solution and Zovia 1/35

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Mycophenolate mofetil may reduce the blood levels and effects of ethinyl estradiol, which may make it less reliable as a form of birth control. Alternative or additional methods of birth control should be used during treatment with mycophenolate mofetil to avoid unintended pregnancy. This is particularly important because mycophenolate mofetil may cause pregnancy loss in the first trimester and also birth defects in the unborn child. Talk to your gynecologist or other healthcare professional for help in selecting an effective method of birth control that is best for you. If you take hormone replacement for menopause, you should contact your doctor if you experience increased frequency or worsening of your symptoms such as hot flashes, vaginal dryness, or abnormal bleeding. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones. The mechanism of interaction has not been established. In 18 women with psoriasis who were studied over 3 consecutive menstrual cycles, administration of combined oral contraceptives containing ethinyl estradiol (0.02 to 0.04 mg) and levonorgestrel (0.05 to 0.20 mg), desogestrel (0.15 mg), or gestodene (0.05 to 0.10 mg) during treatment with mycophenolate mofetil 1 gram twice daily resulted in a 15% reduction in mean levonorgestrel systemic exposure (AUC). No significant changes in mean AUC for ethinyl estradiol and 3-keto desogestrel were observed. However, there was a large interpatient variability in the data, especially for ethinyl estradiol. Mean serum levels of LH, FSH, and progesterone were not significantly affected in the study.

MANAGEMENT: Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms. Because use of mycophenolic acid is associated with an increased risk of pregnancy loss in the first trimester and congenital malformations, it is particularly important that female patients not become pregnant during treatment. An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) should be used in addition to the hormonal contraceptive of choice during the entire duration of mycophenolic acid therapy and for 6 weeks after discontinuation. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.

Mycophenolate Mofetil Injection Solution

Generic Name: mycophenolate mofetil

Brand name: Cellcept, Myfortic, MMF

Synonyms: Mycophenolate mofetil (oral/injection), Mycophenolate

What is Mycophenolate Mofetil Injection Solution?

Zovia 1/35

Generic Name: ethinyl estradiol / ethynodiol

Brand name: Kelnor, Zovia 1/35, Zovia 1/50, Demulen 1/35, Demulen 1/50, Zovia 1/35e, Kelnor 1/50, Kelnor 1/35, Zovia 1/50e

Synonyms: Zovia 1/35E

What is Zovia 1/35?